

Research Article

Synthesis of ^{13}C and ^{15}N multilabeled 5-aminolevulinic acid

Katsumi Iida and Masahiro Kajiwara*

*Department of Medicinal Chemistry, Meiji Pharmaceutical University,
2-522-1 Noshio, Kiyose-shi, Tokyo 204-8588, Japan*

Summary

5-[4- ^{13}C , ^{15}N]- and 5-[5- ^{13}C , ^{15}N]Aminolevulinic acid (ALA) were simply synthesized in four steps by the condensation of [1- ^{13}C , ^{15}N]- or [2- ^{13}C , ^{15}N]glycine, respectively, with phthalic anhydride, followed by conversion to the chloride, coupling reaction with a three-carbon unit and hydrolysis. Copyright © 2002 John Wiley & Sons, Ltd.

Key Words: 5-[4- ^{13}C , ^{15}N]aminolevulinic acid; 5-[5- ^{13}C , ^{15}N]aminolevulinic acid; [1- ^{13}C , ^{15}N]glycine; [2- ^{13}C , ^{15}N]glycine

Introduction

We have developed various methods for the synthesis of regioselectively stable-isotope-labeled 5-aminolevulinic acid (ALA),^{1,2} which is a precursor of porphyrins, for use in studies on the biosynthesis of porphyrins.^{3–5} Synthetic methods of ALA isotope-labeled on C-5 have been reported by Shemin *et al.*,⁶ Battersby *et al.*⁷ and from our laboratory,¹ but involve many steps between introduction of the labeled carbon and formation of the final product. We present here a simple synthesis of [5- ^{13}C , ^{15}N]ALA from [2- ^{13}C , ^{15}N]glycine, and of [4- ^{13}C , ^{15}N]ALA from [1- ^{13}C , ^{15}N]glycine.

*Correspondence to: M. Kajiwara, Department of Medicinal Chemistry, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose-shi, Tokyo 204-8588, Japan.

Results and discussion

As shown in Scheme 1, the condensation of [2- ^{13}C , ^{15}N]glycine (**1**) and phthalic anhydride (**2**) gave 2-[^{15}N]phthalimido[2- ^{13}C]acetic acid (**3**) in 86% yield. The transhalogenation of ethyl 3-bromopropionate (**5**) with sodium iodide in 2-butanone gave ethyl 3-iodopropionate (**6**) in 95% yield. The coupling reaction^{8,9} of 2-[^{15}N]phthalimido[2- ^{13}C]acetyl chloride (**4**), which was derived from 2-[^{15}N]phthalimido[2- ^{13}C]acetic acid (**3**) and thionyl chloride, with 2-ethoxycarbonyl ethylzinc iodide, which was derived from ethyl 3-iodopropionate (**6**) treated with zinc-copper couple, catalyzed by tetrakis(triphenylphosphine)palladium (0) in dry toluene and dry *N,N*-dimethylacetamide gave ethyl 5-[^{15}N]phthalimido[5- ^{13}C]levulinate (**7**) in 92% yield. Finally, hydrolysis of ethyl 5-[^{15}N]phthalimido[5- ^{13}C]levulinate (**7**) in 6 N hydrochloric acid gave [5- ^{13}C , ^{15}N]ALA (**8**) in 89% yield. [4- ^{13}C , ^{15}N]ALA was similarly synthesized from [1- ^{13}C , ^{15}N]glycine in four steps.


Experimental

Materials

[1- ^{13}C , ^{15}N]- and [2- ^{13}C , ^{15}N]Glycine (99at% ^{13}C , 99at % ^{15}N) were purchased from Masstrace, Inc. All other chemicals were of analytical grade.

Instruments

Melting point determinations were carried on a Yanaco micro melting point apparatus, Model MP; values are uncorrected. IR spectra were



Scheme 1. Synthesis of [5- ^{13}C , ^{15}N]ALA (**8**)

recorded on a Jasco VALOR-III FT-IR spectrometer. ^1H -NMR (300 MHz) and ^{13}C -NMR (75 MHz) spectra were recorded on a Varian GEMINI-300 spectrometer. EI- and FAB-MS spectra were obtained on a Jeol DX302 spectrometer.

2-[^{15}N]Phthalimido[2- ^{13}C]acetic acid (**3**)

[2- ^{13}C , ^{15}N]Glycine (**1**) (1.0 g, 13.0 mmol) and phthalic anhydride (**2**) (2.0 g, 13.5 mmol) were heated at 160°C , until the whole was melted. After cooling, the residue was recrystallized from water to give 2-[^{15}N]phthalimido[2- ^{13}C]acetic acid (**3**) (2.3 g, 86%), m.p. $193\text{--}195^\circ\text{C}$; ^1H -NMR (CDCl_3) δ : 4.49 (dd, 2H, $J = 142.3$ Hz, $^2J = 1.1$ Hz), 7.75–7.92 (m, 4H); ^{13}C -NMR (CDCl_3) δ : 38.4 (d, $J = 13.3$ Hz); FT-IR (KBr) cm^{-1} : 1745, 2928; EI-MS m/z (rel. int. %): 207 (M^+ , 4), 162 (100).

Analytical data of 2-[^{15}N]phthalimido[1- ^{13}C]acetic acid, m.p. $191\text{--}194^\circ\text{C}$; ^1H -NMR (CDCl_3) δ : 4.50 (dd, 2H, $^2J = 5.8$ Hz, $^2J = 1.1$ Hz), 7.75–7.92 (m, 4H); ^{13}C -NMR (CDCl_3) δ : 171.6; FT-IR (KBr) cm^{-1} : 1726, 2926; EI-MS m/z (rel. int. %): 207 (M^+ , 4) 161 (100).

Ethyl 3-iodopropionate (**6**)

A suspension of ethyl 3-bromopropionate (**5**) (10 ml, 78.0 mmol) and NaI (17 g, 113.4 mmol) in 2-butanone (100 ml) was refluxed at 90°C for 16 h under argon. After cooling, the crystals were removed by filtration. The filtrate was evaporated, diluted with ether, and washed with brine. Distillation of the crude product gave ethyl 3-iodopropionate (**6**) (33.7 g, 95%), b.p. 105°C (20 mm Hg); ^1H -NMR (CDCl_3) δ : 1.29 (t, 3H, $J = 7.1$ Hz), 2.97 (t, 2H, $J = 7.1$ Hz), 3.34 (t, 2H, $J = 7.1$ Hz), 4.19 (q, 2H, $J = 7.1$ Hz); FT-IR (neat) cm^{-1} : 1730; EI-MS m/z (rel. int. %): 228 (M^+ , 100), 155 (61), 101 (92), 73 (47).

Ethyl 5-[^{15}N]phthalimido[5- ^{13}C]levulinate (**7**)

A mixture of 2-[^{15}N]phthalimido[2- ^{13}C]acetic acid (**3**) (2.3 g, 11.1 mmol) and thionyl chloride (30 ml) was refluxed at 80°C for 18 h. The excess thionyl chloride was removed *in vacuo*. The residue was dissolved in dry

toluene (3 ml) and evaporated. This process was repeated twice, and the resulting 2-[^{15}N]phthalimido[2- ^{13}C]acetyl chloride (**4**) was dissolved in dry toluene (5 ml) under argon. Ethyl 3-iodopropionate (**6**) (2.82 g, 12.4 mmol) was added to a suspension of Zn–Cu couple (1.0 g) in dry toluene (1.2 ml) and dry *N,N*-dimethylacetamide (14 ml) under argon, and the mixture was heated at 60°C for 15 h. To this suspension, a suspension of $\text{Pd}(\text{PPh}_3)_4$ (530 mg, 459 μmol) in dry toluene (5 ml) under argon was added, and the whole was stirred at 60°C for 5 min. To this suspension, a solution of 2-[^{15}N]phthalimido[2- ^{13}C]acetyl chloride (**4**) was added, and the whole was stirred at 60°C for 25 min. The reaction was diluted with ethyl acetate (300 ml), and the whole was washed with 1 N HCl, sat. NaHCO_3 and brine, dried over dry MgSO_4 , and evaporated. Chromatography of the crude product on silica gel with ethyl acetate:hexane (1:1) gave ethyl 5-[^{15}N]phthalimido[5- ^{13}C]levulinate (**7**) (2.98 g, 92%), m.p. 75–77°C; ^1H -NMR (CDCl_3) δ : 1.26 (t, 3H, $J = 7.1$ Hz), 2.66 (t, 2H, $J = 6.6$ Hz), 2.85 (t, 2H, $J = 6.6$ Hz), 4.15 (q, 2H, $J = 7.1$ Hz), 4.56 (d, 2H, $J = 139.8$ Hz), 7.73–7.89 (m, 4H); ^{13}C -NMR (CDCl_3) δ : 46.5 (d, $J = 12.2$ Hz); FT-IR (KBr) cm^{-1} : 1725, 1771, 2920; EI-MS m/z (rel. int. %): 291 (M^+ , 2), 162 (44), 129 (100), 101 (75).

Analytical data of ethyl 5-[^{15}N]phthalimido[4- ^{13}C]levulinate, m.p. 73–76°C; ^1H -NMR (CDCl_3) δ : 1.26 (t, 3H, $J = 7.1$ Hz) 2.67 (q, 2H, $J = 6.6$ Hz), 2.86 (q, 2H, $J = 6.6$ Hz), 4.15 (q, 2H, $J = 7.1$ Hz), 4.57 (dd, 2H, $^2J = 3.8$ Hz, $^2J = 1.1$ Hz), 7.73–7.89 (m, 4H); ^{13}C -NMR (CDCl_3) δ : 200.8; FT-IR (KBr) cm^{-1} : 1726, 1770, 2916; EI-MS m/z (rel. int. %): 291 (M^+ , 1), 161 (100), 130 (50), 102 (37).

[5- ^{13}C , ^{15}N]ALA hydrochloride (**8**)

A solution of ethyl 5-[^{15}N]phthalimido[5- ^{13}C]levulinate (**7**) (1.38 g, 4.7 mmol) in 6 N HCl (6 ml) was refluxed at 110°C for 14 h. The reaction mixture was cooled to room temperature and filtrated. The filtrate was washed with ether and evaporated. The residue was recrystallized from EtOH–ether to give [5- ^{13}C , ^{15}N]ALA hydrochloride (**8**) (717 mg, 89%), m.p. 144–147°C; ^1H -NMR (D_2O) δ : 2.72 (t, 2H, $J = 6.2$ Hz), 2.90 (t, 2H, $J = 6.2$ Hz), 4.13 (d, 2H, $J = 143.9$ Hz); ^{13}C -NMR (D_2O) δ : 49.8 (d, $J = 7.7$ Hz); FT-IR (KBr) cm^{-1} : 1695, 1725, 2927; FAB-MS (glycerol) m/z : 134 ($\text{MH}^+ - \text{HCl}$).

Analytical data of [4- ^{13}C , ^{15}N]ALA hydrochloride, m.p. 146–149°C; ^1H -NMR (D_2O) δ : 2.72 (q, 2H, $J = 6.0$ Hz), 2.90 (q, 2H, $J = 6.0$ Hz),

4.13 (d, 2H, $J=4.2$ Hz); ^{13}C -NMR (D_2O) δ : 206.8; FT-IR (KBr) cm^{-1} : 1685, 1725, 3005; FAB-MS (glycerol) m/z : 134 ($\text{MH}^+ - \text{HCl}$).

References

1. Kurumaya K, Okazaki T, Seido N, Akasaka Y, Kawajiri Y, Kajiwaru M, Kondo M. *J Labelled Cpd Radiopharm* 1989; **27**: 217–235.
2. Iida K, Takao Y, Ogai T, Kajiwaru M. *J Labelled Cpd Radiopharm* 1997; **39**: 797–802.
3. Okazaki T, Kurumaya K, Kajiwaru M. *Chem Pharm Bull* 1990; **38**: 1727–1730.
4. Kajiwaru M, Hara K, Mizutani M, Kondo M. *Chem Pharm Bull* 1992; **40**: 3321–3323.
5. Spencer JB, Stolowich NJ, Santander PJ, Pichon C, Kajiwaru M, Tokiwa S, Takatori K, Scott AI. *J Am Chem Soc* 1994; **116**: 4991–4992.
6. Shemin D, Russell CS, Abramsky T. *J Biol Chem* 1955; **215**: 613–626.
7. Battersby AR, Hunt E, McDonald E, Moron J. *J Chem Soc, Perkin Trans 1* **1973**: 2917–2922.
8. Tamaru Y, Ochiai H, Sanda F, Yoshida Z. *Tetrahedron Lett* 1985; **26**: 5529–5532.
9. Tamaru Y, Ochiai H, Nakamura T, Tsubaki K, Yoshida Z. *Tetrahedron Lett* 1985; **26**: 5559–5562.